stockrow
Friday 6 November 2026
Export PLRX’s income statement to Excel — free account
Pliant Therapeutics, Inc.
PLRX Healthcare Biotechnology
Pliant Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $1.6 million, down 83.7% from fiscal 2022.
- EPS
- +49.3%
- Free cash flow
- +68.6%
Quarter to June 2026, against a year earlier
0.81
0.01
−1.22%
Follow PLRX
Alert me
Pliant Therapeutics, Inc. (PLRX) P/E ratio
Pliant Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 11.8× (March 2021) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 6.7× | 380.59% |
| FY2019 | 1.4× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2023 | 0.0× | — |
| Mar 2023 | 0.0× | — |
| Dec 2022 | 0.0× | — |
| Sep 2022 | 0.0× | — |
| 11 more quarters | Free account |
Against its own ten years
Low 0.0×
High 11.8×
Ten-year median
0.0×
Current reading's percentile
87
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| KLRS Kalaris Therapeutics Inc. compare | n/m |
| HOWL Werewolf Therapeutics, Inc. compare | n/m |
| RNTX Rein Therapeutics Inc. compare | n/m |
| ELOX Senesco Technologies Inc. compare | n/m |
| APLM Apollomics Inc. compare | n/m |
| ALPS Alps Group Inc. compare | n/m |
| PLRX Pliant Therapeutics, Inc. | n/m |
| INKT MiNK Therapeutics, Inc. compare | n/m |
| OSTX OS Therapies Incorporated compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)